US Market Changes in the Treatment of Advanced Prostate Cancer
Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and 2012 to compare oncology practice patterns and determine trends across time in the management of advanced prostate cancer. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing U.S. oncologists on the treatment of patients with advanced prostate cancer.
CHAPTER 1: INTRODUCTION
CHAPTER 2: RESPONDENT DEMOGRAPHICS
CHAPTER 3: TREATMENT OF A PATIENT WITH INCREASED PSA AND ADENOCARCINOMA
CHAPTER 4: ELDERLY PATIENT TREATED FOR GLEASON’S 7 ADENOCARCINOMA, INCREASED PSA 18 MONTHS LATER
CHAPTER 5: PATIENT WITH GLEASON’S 3+4 ADENOCARCINOMA AND MULTIPLE METASTASES TO PELVIS AND SPINE DEVELOPS CASTRATION-RESISTANT DISEASE
CHAPTER 6: ELDERLY PATIENT WITH GLEASON’S 5+5 AND MULTIPLE METASTASES
APPENDIX A: SURVEY INSTRUMENT
CHAPTER 2: RESPONDENT DEMOGRAPHICS
CHAPTER 3: TREATMENT OF A PATIENT WITH INCREASED PSA AND ADENOCARCINOMA
CHAPTER 4: ELDERLY PATIENT TREATED FOR GLEASON’S 7 ADENOCARCINOMA, INCREASED PSA 18 MONTHS LATER
CHAPTER 5: PATIENT WITH GLEASON’S 3+4 ADENOCARCINOMA AND MULTIPLE METASTASES TO PELVIS AND SPINE DEVELOPS CASTRATION-RESISTANT DISEASE
CHAPTER 6: ELDERLY PATIENT WITH GLEASON’S 5+5 AND MULTIPLE METASTASES
APPENDIX A: SURVEY INSTRUMENT
